This combined viro-immunotherapeutic approach synergizes to overcome adaptive immune resistance induced by intratumoral PD-1 expressing CD8+ T cells, leading to an effective IFNγ-mediated antitumor immune response and long-term cure of glioma-bearing mice. This evidence concerns the gene CD8A and central nervous system cancer.